The deal is the result of restructuring a collaboration, which began in 2020 to develop mRNA-based vaccines for infectious diseases, into a new licensing agreement, GSK added. As a result of the collaboration, the two companies have vaccine candidates for seasonal influenza and COVID-19 in phase II clinical development and avian influenza in phase I clinical development.
Breaking
ICE agents arrested an illegal alien with 67 criminal arrests, 17 other dangerous illegals, and a man who slashed an agency vehicle tire....
Microsoft is ending its use of China-based engineers for Pentagon cloud systems after an investigation revealed security vulnerabilities in its "digital escort" program....
loading...